Table 3 absolute differences in Disease Activity Score (DAS)28 and Health Assessment Questionnaire (HAQ) results from baseline and the European League Against Rheumatism (EULAR) response percentages (good and moderate added) at 3, 6, 9 and 12 months
AdalimumabEtanerceptInfliximab
DAS28
Baseline5.3 (1.3)5.5 (1.2)5.2 (1.3)
3 months:
    Decrease−1.6 (1.3)*−1.5 (1.2)*−0.9 (1.5)
    EULAR response (%)76%*74%*57%
6 months:
    Decrease−1.8 (1.4)*−1.6 (1.3)*−1.1 (1.4)
    EULAR response (%)78%*75%*57%
9 months:
    Decrease−1.8 (1.4)*−1.9 (1.4)*−1.1 (1.3)
    EULAR response (%)79%*79%*62%
12 months:
    Decrease−1.8 (1.5)*−1.8 (1.4)*−1.2 (1.4)
    EULAR response (%)78%*80%*61%
HAQ
Baseline1.3 (0.7)1.4 (0.7)1.4 (0.7)
3 months:
    Decrease−0.35 (0.5)*−0.33 (0.5)*−0.19 (0.5)
6 months:
    Decrease−0.42 (0.5)*−0.35 (0.5)−0.23 (0.5)
9 months:
    Decrease−0.40 (0.5)*−0.36 (0.6)−0.26 (0.5)
12 months:
    Decrease−0.42 (0.6)*−0.35 (0.6)−0.26 (0.5)

  • Values are means with standard deviations between brackets unless stated otherwise. Missing values at baseline, 3, 6, 9, 12 months, respectively: DAS28, 5.1%, 4.0%, 10.6%, 12.6%, 15.1%; HAQ, 9.9%, 9.2%, 12.2%, 15.6%, 16.3%

  • *Significant difference (<0.05) compared to infliximab patients.